

# Glanzmann Thrombasthenia Panel

---

**Versiti offers comprehensive genetic analysis to detect sequence variants and large deletions and duplications in 2 genes known to cause Glanzmann thrombasthenia. This panel can be ordered as:**

- **Next generation sequencing (NGS) only;**
- **NGS with reflex to array Comparative Genomic Hybridization (aCGH) deletion/duplication analysis if biallelic clinically significant variants are not detected by sequencing;**
- **NGS analysis with concurrent aCGH deletion/duplication analysis (both testing methodologies performed simultaneously); or**
- **Deletion/duplication analysis by aCGH only.**

---

Glanzmann thrombasthenia (GT) is an autosomal recessive bleeding disorder characterized by platelet dysfunction due to quantitative or qualitative defects in the platelet glycoprotein (GP) receptor IIb/IIIa. The GPIIb/IIIa complex is the platelet receptor for fibrinogen and also binds von Willebrand factor (VWF) and fibronectin. Activation of this complex is essential for platelet aggregation. The glycoproteins IIb (GPIIb) and IIIa (GPIIIa), encoded by the *ITGA2B* and *ITGB3* genes respectively, are both required for efficient expression of the complex on the platelet surface.

Autosomal recessive Glanzmann thrombasthenia, caused by loss of function variants in *ITGA2B* and *ITGB3*, is a rare disorder with an estimated incidence of 1 in one million births. It affects males and females equally and while it has been described all over the world, a large proportion of cases have been reported in the French Romani,

South Indian Hindu, Iraqi Jewish and Jordanian nomadic tribes, where consanguinity is more common. Patients typically present with moderate to severe bleeding, with normal platelet count and abnormal platelet function with absent or markedly reduced aggregation response to all agonists except ristocetin. In cases of quantitative GPIIb/IIIa deficiency, flow cytometric analysis demonstrates decreased or absent expression of GPIIb (CD41) and GPIIIa (CD61) on the platelet surface.

Pathogenic gain of function variants that lead to constitutive activation of GPIIb/IIIa and interfere with proplatelet formation are associated with mild autosomal dominant macrothrombocytopenia. Most of the pathogenic variants associated with this phenotype are in *ITGB3* and affect the metal ion binding sites; however, they have also been reported in the conserved intracellular sequence of *ITGA2B*.

The NGS panel evaluates for single nucleotide variants and small deletions and duplications, which are most commonly responsible for genetic disease. However, large deletions and duplications, also referred to as copy number variations (CNVs), are a known cause of genetic disorders, but can escape detection by next generation sequence analysis. Additional testing with aCGH Deletion/Duplication analysis is available for all genes on this panel to evaluate for large deletions and duplications encompassing one or more exons, or affecting an entire gene.

Refer to the table for further information about each gene in the Glanzmann Thrombasthenia Panel, including the clinical phenotype and inheritance pattern.

## Glanzmann Thrombasthenia Panel: gene, clinical phenotype, population-specific comments and inheritance pattern

Gene	Clinical Phenotype	Inheritance
ITGA2B	<b>Glanzmann thrombasthenia:</b> normal platelet count with severe bleeding and decreased/absent platelet aggregation with all agonists except ristocetin due to decreased/absent/dysfunctional expression of platelet glycoprotein (GP) IIb/IIIa	Autosomal Recessive
	<b>ITGA2B-related macrothrombocytopenia:</b> mild to moderate thrombocytopenia with absent/mild bleeding	Autosomal Dominant
ITGB3	<b>Glanzmann thrombasthenia:</b> normal platelet count with severe bleeding and decreased/absent platelet aggregation with all agonists except ristocetin due to decreased/absent/dysfunctional expression of platelet glycoprotein (GP) IIb/IIIa	Autosomal Recessive
	<b>ITGB3-related macrothrombocytopenia:</b> mild to moderate thrombocytopenia with absent/mild bleeding	Autosomal Dominant

### Indications for testing:

#### Glanzmann Thrombasthenia Panel (NGS and/or aCGH), order code 4870:

The Glanzmann Thrombasthenia Panel should be considered:

- In patients presenting with the specific phenotype of lifelong moderate/severe bleeding, normal platelet count with normal platelet granularity, decreased/absent platelet aggregation with all agonists except ristocetin and/or decreased/absent GPIIb/IIIa expression on platelet flow cytometry.
- To clarify possible carrier status in individuals who have a family history of a Glanzmann thrombasthenia, but the causal familial variant(s) is unknown.

#### Single Gene Analysis (order code 4855) or Custom Blood Disorder Panel (Order Code 4850), (NGS and/or aCGH):

Analysis of genes included in this panel may also be ordered as standalone Single Gene Analysis or as a Custom Blood Disorder Panel (2-10 genes), by NGS and/or by aCGH, as dictated by the patient's clinical and laboratory phenotype, as well as their ancestry, or to supplement previous genetic testing.

#### Targeted Familial Variant Analysis (order code 4970):

Targeted variant analysis for clinical diagnosis, carrier identification, or prenatal diagnosis can also be performed on any gene in the panel when the pathogenic variant(s) is known in the family. If the proband was not tested at Versiti, a control sample is preferred and may be required (please call the laboratory to discuss). If the familial variant is a large deletion or duplication, aCGH for the involved gene is required.

For clinical questions about laboratory tests and test utilization support, contact Versiti Client Services: (414) 937-6396 or 800-245-3117, Option 1, to be directed to our genetic counselors and clinical support team.

### Test method:

**NGS:** This next-generation sequencing assay analyzes the complete coding region of 2 genes plus a minimum 30bp of non-coding DNA, including intron-exon boundaries, and is compared to the build GRCh37.p13 reference sequence. These targeted regions are captured by hybridization, amplified, and sequenced by massively parallel sequencing. Regions will have a minimum coverage of 50x and those regions with less than 50 sequencing reads or low quality coverage are supplemented with Sanger sequencing. All regions are covered by bidirectional analysis. Variants are identified by a customized bioinformatics pipeline, analyzed and comprehensively interpreted by our team of practicing hematologists with expertise in non-malignant hematology and laboratory diagnostics, scientists, and genetic counselors. All reported variants, including pathogenic, likely pathogenic, and variants of uncertain significance, are confirmed by Sanger sequencing. For prenatal testing, analysis of variable number tandem repeats (VNTR) is used to confirm results are not affected by maternal cell contamination.

**aCGH:** The specific genes are analyzed for copy number variations due to deletion or duplication by high density gene-focused array Comparative Genomic Hybridization. Probes are approximately 60bp in length and density of coverage in exonic regions is a minimum of 4 probes per 500 bp. Genomic DNA for the samples and sex-matched references are denatured, labeled with fluorescent dye and hybridized, the array is washed and scanned, and analysis is performed for the specific genes requested.

### Assay sensitivity and limitations:

**NGS:** The analytical sensitivity of the NGS test is >99% for single nucleotide changes and insertions and deletions of less than 20 bp. NGS analysis is not designed to detect large deletions or duplications (>20 bp), or variants that are outside the regions sequenced. Low level mosaicism will not be detected by this sequencing methodology.

**aCGH:** Balanced chromosomal rearrangements (i.e., translocations, inversions) or point mutations that may be the cause of the clinical phenotype cannot be detected via aCGH. Any exonic deletion or duplication smaller than 500bp may not be detected. Low level of mosaicism will not be detected by aCGH. Probe performance could be affected by multiple SNPs in a given region. Breakpoints occurring outside the targeted gene(s) will not be defined.

### Clinical Sensitivity

The clinical sensitivity of comprehensive genetic testing (NGS and aCGH) of the 2 genes known to be associated with GT is highest in patients with the classic presentation of bleeding, normal platelet count with normal granularity, decreased/absent platelet aggregation with all agonists except ristocetin and decreased GPIIb/IIIa expression on platelet flow cytometry. The autosomal dominant macrothrombocytopenia phenotype is not specific and cannot be easily clinically distinguished from other inherited thrombocytopenias with normal/large platelet size. In that specific context, the clinical diagnostic yield of this panel is expected to be low and the Inherited Thrombocytopenia Panel or Autosomal Dominant Thrombocytopenia Panel is recommended, as it would have higher clinical sensitivity.

### Reporting of Results

Results are classified and reported in accordance with ACMG next-generation sequencing and copy number variation standards. Sequence variants and large deletions and duplications predicted to be pathogenic, likely pathogenic, and of uncertain significance will be reported; variants classified as likely benign or benign are typically not reported but such data are available upon request. Sequence variants are described using standard Human Genome Variation Society (HGVS) nomenclature (<http://hgvs.org>); copy number variants are described in accordance with the International System for Human Cytogenomic Nomenclature (ISCN).

### Specimen Requirements

**Parental/Patient/Pediatric:** 3-5 mL Whole blood (EDTA tube, lavender top), 2-5 mL Bone marrow (EDTA tube, lavender top), 3-4 Buccal swabs, or  $\geq 1\mu\text{g}$  of DNA at  $\geq 50\text{ng}/\mu\text{L}$  of High Quality DNA.

**Fetal:** 7-15 mL amniotic fluid, 5-10 mg chorionic villi; back up culture of amniocytes or chorionic villi is highly recommended. Cultured: Two T25 flasks cultured amniocytes or chorionic villi ( $2 \times 10^6$  minimum). Maternal blood sample of 3-5 mL Whole blood (EDTA tube, lavender top) is requested for all prenatal samples for maternal cell contamination studies. For questions please contact the laboratory to discuss sample requirements.



### SHIP

### Shipping Requirements

Ship on an ice pack or at room temperature. Protect from freezing. Place the specimen and the requisition into plastic bags and seal. Insert into a Styrofoam container, seal and place into a sturdy cardboard box, and tape securely. Ship the package in compliance with your overnight carrier guidelines. Label with the following address:

Client Services/Diagnostic Laboratory  
Versiti  
638 N. 18th St  
Milwaukee, WI, 53233



### ORDER

### Required Forms

Please complete all pages of the requisition form. Clinical history (including patient-reported ancestry, clinical diagnosis, family history, and relevant laboratory findings) is necessary for optimal interpretation of genetic test results and recommendations. Clinical and laboratory history can either be recorded on the

requisition form or clinical and laboratory reports can be submitted with the sample.

### CPT Codes/Billing/Turnaround Time

**Test code:** 4870

For suggested CPT codes, visit [Versiti.org/test-catalog](https://www.versiti.org/test-catalog)

**Turnaround time:** NGS only, aCGH only, or NGS and aCGH concurrently: 21 days

NGS reflex to aCGH: 21 days (if NGS only, aCGH not needed) or 42 days (with reflex to aCGH)

The CPT codes provided are subject to change as more information becomes available. CPT codes are provided only as guidance to assist clients with billing.

For additional information related to shipping, billing or pricing, please contact Versiti Client Services: (414) 937-6396 or 800-245-3117, Option 1, or [LabInfo@versiti.org](mailto:LabInfo@versiti.org)

## References

### Glanzmann thrombasthenia references

1. Botero JP, Lee K, Branchford BR, et al. Glanzmann thrombasthenia: genetic basis and clinical correlates. *Haematologica*. 2020;105(4):888-894. doi:10.3324/haematol.2018.214239
2. Kashiwagi H, Kunishima S, Kiyomizu K, et al. Demonstration of novel gain-of-function mutations of  $\alpha$ IIb $\beta$ 3: association with macrothrombocytopenia and glanzmann thrombasthenia-like phenotype. *Mol Genet Genomic Med*. 2013;1(2):77-86. doi:10.1002/mgg3.9
3. Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. *Blood*. 2011;118(23):5996-6005. doi:10.1182/blood-2011-07-365635
4. Nurden AT, Pillois X. ITGA2B and ITGB3 gene mutations associated with Glanzmann thrombasthenia. *Platelets*. 2018;29(1):98-101. doi:10.1080/09537104.2017.1371291

### Variant interpretation references

5. Bean LJH, Funke B, Carlston CM, et al. Diagnostic gene sequencing panels: from design to report-a technical standard of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2020;22(3):453-461. doi:10.1038/s41436-019-0666-z
6. Rehm HL, Bale SJ, Bayrak-Toydemir P, et al. ACMG clinical laboratory standards for next-generation sequencing. *Genet Med*. 2013;15(9):733-747. doi:10.1038/gim.2013.92
7. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17(5):405-424. doi:10.1038/gim.2015.30
8. Riggs ER, Andersen EF, Cherry AM, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). *Genet Med*. 2020;22(2):245-257. doi:10.1038/s41436-019-0686-8

